Addition of liraglutide to overweight patients with type 2 diabetes treated with multiple daily insulin injections (MDI) with inadequate glycaemic control

Trial Profile

Addition of liraglutide to overweight patients with type 2 diabetes treated with multiple daily insulin injections (MDI) with inadequate glycaemic control

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 13 Jun 2017 Results assessing factors associated with HbA1c and weight changes, presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 28 Oct 2015 Primary endpoint (Change in HbA1c) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top